chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This is a 45 year old who had been in his usual health when he deployed in April 2003. He was deployed with a T-3 profile secondary to bilateral feet and knee pain/problems. He was taken 500mg of Motrin three (3) times a day, Naprosyn 300mg two (2) times a day, and malaria med once (1) a day.  During the month of March 2003, he received multiple vaccines (Anthrax X3, non-primary smallpox, Td, Hep A, Meningococcal, Typhoid, MMR and influenza). He received his non-primary smallpox vaccination on 08 March 2003. He began experiencing chest discomfort in April 2003, with associated shortness of breath on exertion.  He states that the dyspnea was worse when he was trying to run or climb stairs and accompanied a more intense chest discomfort. He did not seek medical attention at that time. Currently, he is still experiencing daily chest discomfort (2/10 at rest; 5-9/10 with exertion). He characterizes his pain as sometimes stabbing pain and other times it is a dull ache. He continues to have some associated dyspnea with the chest pain. Approximately one (1) month after arriving overseas he began having problems with his stomach, i.e. nausea, which continued during entire deployment. He was taking Mefloquine for malaria prophylaxis. At the end of April 2003, he fell backwards over a sand bag and landed "flat on my back".  He began experiencing headaches which were much worse while in full gear/Kevlar®. He also was bitten by a "baby camel spider".  Approximately two (2) months later [July/August 2003] he was seen in the medical unit for high blood pressure. He was placed on medication, which he is uncertain of the name. He took the medicine for less than a week and was taken off it secondary low blood pressure. During this same timeframe he began running a fever, unmeasured, became more nauseated. These symptoms lasted approximately three (3) weeks, with the nausea lasting for several months. Approximately five (5) months after arriving, he began experiencing eruptions of "water-filled blisters" on his 4th & 5th digits left hand, denies any itching. The blisters turned into hard bumps and resolved after approximately four (4) weeks. He has "small red raised itchy bumps" predominately on his upper chest and upper back, worse on his head, face and extremities. These eruptions last a week to ten days, leaving a dark spot on his skin. He states that he has been evaluated for the itching. The provider felt that it was related to a medication that he was taking. However upon cessation of the medication, the rash persists.
A physician reported that a 36 year old female received an injection of influenza virus vaccine on an unspecified date. Eight days, post vax, the pt was hospitalized with meningitis. Additional information has been requested.
This patient presented on 2.1.22 requesting COVID-19 1st dose vaccine. Pt was provided 0.5 ml IM R Deltoid. Staff later realized patient would not be 18 years old until 3.4.22. No adverse reactions were reported by patient.
I got a fever 101.0 of and I was fatigue and I had a cough. COVID home test was positive. The cough lasted for two to three weeks after. I had running nose and my feet and hands were really cold. My body was hurting. I also had a headache. I have a pain in my back.
Skin became itchy around site of shot (left arm) within 2 hrs. Arm became very sore by late afternoon, Noticed considerable swelling, redness. Heat the next morning, returned to normal by 11-21. Got flu shot in right arm had temperature and chills early evening until next day use ice and take pain reliever.
This spontaneous report was received from a pharmacist via a company representative, referring to a patient of unknown age and gender. The patient's concurrent conditions, medical history and concomitant therapies were not provided. On approximately 02-FEB-2016 (reported as 3 weeks before 23-FEB-2016) the patient was vaccinated with ZOSTAVAX injection (lot number, expiry date, dose, administration route, anatomical site of injection and frequency were not reported). In 2016, the patient required to be treated with HUMIRA for an unspecified reason. At the time of this report, the outcome of adverse event was unknown. The reporter did not provide a causality between the reported event and the administration of ZOSTAVAX. Additional information has been requested.
This spontaneous report as received from a medical assistant via a company representative and refers to a 3 year old patient of unknown gender. On an unknown date the patient was vaccinated with (oka/merck) VARIVAX (dose, units, route of administration, anatomical location, lot number were not reported). On 14-JUL-2014 the symptoms of chickenpox occurred (described as spots and fever) which was diagnosed as chickenpox (diagnosed on 21-JUL-2014). On 21-JUL-2014 the patient sought medical attention. The outcome of event was reported as not recovered. The relatedness between event and (oka/merck) VARIVAX was not reported. Follow-up information has been received from a medical assistant. The reporter stated a VAERS (Vaccine Adverse Event Reporting System) report had been filed and additional information regarding patient was available at that time. The reporter also stated if any additional information becomes available she may fax that information. This is one of several reports from the same reporter. Additional information is not expected because address was correctly entered but the correspondence was returned.
On 5/5/13 pt calls to report increased left upper arm pain after TDAP 0.5 ml IM given on 4/29/13. She states the injection site is not red and is not swollen. She does report tingling sensation to left had at times, like it's asleep and waking up. Seen by physician on 5/6/13. S: is c/o pain on moving the left shoulder joint and no fall or any injury to the left upper extremity. Left shoulder ROM restricted and also c/o finger ruing is tight. No pain in the hand, forearm or arm on rest. It becomes painful on moving the shoulder. She denies any pain at shot site today. She has applied moist heat at local injection site.
Fever 99.6F on 12/29/20 @22:41 and on 12/31/20 @03:52 s/p COVID-19 vaccine received on 12/28/20 @13:39. Patient is on standing Acetaminophen 650mg q6h for pain/fever. Acetaminophen 650mg administered 12:29 @22:41 and 12/31 @06:02 with resolution of symptoms. Fever ACETAMINOPHEN 650 MG QID FOR PAIN/FEVER
Leg pain; Trouble walking; Rash on arms; Joint pain; muscle pain; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3184) via an unspecified route of administration in the left arm on 19Sep2021 at 00:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. The patient previously the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3184) via an unspecified route of administration in the left arm on 26Aug2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. On 19Sep2021, the patient experienced leg pain, trouble walking, rash on arms, joint and muscle pain. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with prednisone (MANUFACTURER UNKNOWN). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events leg pain, trouble walking, rash on arms, joint and muscle pain was resolving at the time of this report.
The patient became diaphoretic, bradycardic (30-40's), hypotension, change in level of consciousness.  Oxygen administered and patient improved.  Once oxygen removed, episode repeated.  Sent to ER and he had no further episodes.  He was discharged from the ER.
Within 48 hours post-vaccinations the patient had onset, of indurated, tender slightly erythematous and pruritic areas in each deltoid area. Exam on 7/14 (approx 48 hrs post vaccination) showed 5 x 5.5 cm and 10 x 8 cm areas of induration - not fluctuant - in (R) and (L) deltoid muscle areas, respectively.
Vaccine administered w/ back pain that initiated in lumbar spine w/in 2     minutes post vaccine administration. Pain then radiated up to right     shoulder and down into arm. 911 called, Patient taken to local ED for     evaluation. By the time the ambulance arrived, Patient states pain in back     had gone from a 10/10 down to 3/10. Continued pain in right shoulder and     arm/wrist
Severe Muscle pain throughout my entire left side and severe joint pain left side only. Severe arm pain at the site of injection.  This pain was severe visceral pain  and lasted for over 6+ weeks. Only on my left side. The pain was present when simply sitting as well as during activity. There are still days when the pain returns for no reason at all. The pain is deep inside my left thigh and lower leg.  I need to take ibuprophen to decrease the discomfort.
Booster dose; jaw pain; Sore arm; headache; sinus pressure; earache; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 60 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 24May2021 11:15 (Batch/Lot number: unknown) at the age of 60 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "known allergies: Oral anti Inflammatorys" (unspecified if ongoing); "if covid prior vaccination: Yes" (unspecified if ongoing). Concomitant medication(s) included: THYROXINE.  Vaccination history included: Bnt162b2 ((product=COVID 19, brand=Pfizer, lot unknown=True, lot unknown reason=Unable to locate or read the details, administration date=23Mar2021, administration time=11:15 AM, dose number=1,, vaccine location=Left arm)), administration date: 23Mar2021, when the patient was 60 years old, for COVID-19 immunisation. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious), outcome "unknown", described as "administration date=23Mar2021/administration date=24May2021"; TREMOR (non-serious) with onset 24May2021 23:00, outcome "recovering", described as "Severe shaking after 12hrs.Elevated heart rate during rest Severe drenching night sweat 60 hrs later."; HEART RATE INCREASED (non-serious), NIGHT SWEATS (non-serious) all with onset 24May2021 23:00, outcome "recovering" and all described as "Severe shaking after 12hrs.Elevated heart rate during restSevere drenching night sweat 60 hrs later.". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of inappropriate schedule of product administration, tremor, heart rate increased, night sweats.  Additional information: Patient had not received any other vaccine with in four weeks, No prior vaccination patient has not been taken. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
One day after injection developed moderate to severe joint pain.  Joint pain subsided after 24 hrs.
Fever, shivering, feeling cold in bed, eyes sore.  I think these are in line with the noted possible side effects.  I feel somewhat better today.  I don't have a fever today (June 21).
Patient became unconscious after about 10 minutes after vaccine was given for about 10 seconds. Once consciousness was regained, patient appeared confused and pale. Patient's eyes rolled back and arms and legs were flailing  about during unconscious episode
lot of pain; Swelling; Limited range of motion; This case was reported by a other health professional and described the occurrence of pain in a female patient who received Men B NVS (Bexsero) for prophylaxis.   In August 2019, the patient received the 1st dose of Bexsero. On an unknown date, less than 5 months after receiving Bexsero, the patient experienced pain, swelling and joint range of motion decreased. On an unknown date, the outcome of the pain, swelling and joint range of motion decreased were recovered/resolved.   It was unknown if the reporter considered the pain, swelling and joint range of motion decreased to be related to Bexsero.  Additional details were provided as follows: The age at vaccination was not reported. After vaccination, the patient experienced a lot of pain and swelling with limited range of motion secondary to pain for 2 weeks following the injection. The patient did not felt comfortable to receive 2nd dose of Shingrix whien went to college. The patient's parent asked if get 2nd dose of shingrix though it has been 4 months and because of patient's condition.
Took first dose of Pfizer on 2/14/2021 Sunday, then on 2/17/2021 afternoon a serous tinnitus came up. It is like cicada singing at both of your ears constantly, none stop, and annoying. It keeps happening since that day.  The strange thing is it will last for 2 days, then disappeared, then come back again one or one and half day.
sweating; potential invalid Moderna COVID-19 doses given; body aches; a little bit of fever; This spontaneous case was reported by an other health care professional and describes the occurrence of HYPERHIDROSIS (sweating), PRODUCT PREPARATION ERROR (potential invalid Moderna COVID-19 doses given), MYALGIA (body aches) and PYREXIA (a little bit of fever) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A & 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (sweating), PRODUCT PREPARATION ERROR (potential invalid Moderna COVID-19 doses given), MYALGIA (body aches) and PYREXIA (a little bit of fever). At the time of the report, HYPERHIDROSIS (sweating), MYALGIA (body aches) and PYREXIA (a little bit of fever) outcome was unknown and PRODUCT PREPARATION ERROR (potential invalid Moderna COVID-19 doses given) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported by the reporter. No treatment was reported by the reporter. Moderna vaccine was transported from one clinic to the other in a trip that lasted 5 hours tops. vials were surrounded with icepacks. Temperature was not checked. Two of this conveyances took place. First one on 15Sep2021 (lot #044B21A) while second one on 15Sep2021 (lot #026C21A). HCP said that the conditions were the same for both transportations. Most of the vials were still frozen or starting to thaw (with only a small portion in liquid state). Frozen vials were placed in the freezer while partially thawed were put in the fridge. All doses from carton with lot #044B21A (expired on 21Oct2021) were given; but only 6 vials from carton with lot #026C21A (expires on 06Dec2021) were administered. The remaining 4 vials were confiscated in an audit. Both cartons contained 15-dose vials. Vaccines given included 1st doses, 2nd doses and booster doses.
This case was reported by a physician via call center representative and described the occurrence of hives in a adult female patient who received FLUARIX (batch number AFLUA708BA, expiry date 30th June 2013). Concomitant products included medication unknown. On an unknown date, the patient received FLUARIX. On an unknown date, 2 hrs after receiving FLUARIX, the patient experienced hives. On an unknown date, the outcome of the hives was unknown. The reporter considered the hives to be possibly related to FLUARIX. Additional details provided: The patient did not seek medical attention. The reporter recommended to contact the patient's allergist for any follow-up.
On April 27 I started developing symptoms of shingles and went to my doctor today  and confirmed I have shingles
2/14: The day after receiving the vaccine, she noticed a rash on her chest and legs. She felt nauseous and endorsed vomiting, body aches, and fever.  2/16: Saw PCP and was found hypotensive. Was sent to ED and received 2L fluids, IM steroids, and PO ondansetron. She was discharged because she was feeling better.  2/17: Returned to hospital due to pleuritic chest pain and hemoptysis and was noted to have an elevated lactate (received 3L fluids) and was admitted to the hospital. SpO2 was in the  70s on presentation and she was placed on BiPAP (O2 improved to 100%). Per note: patient presented to the ED with hypoxia, tachycardia, tachypnea, and leukocytosis. Patient received dexamethasone 6mg, vancomycin, cefepime, azithromycin, furosemide, and ipratropium/albuterol.  Patient is currently receiving the following medications: budesonide, ipratropium/albuterol, cefepime, acetaminophen, atorvastatin, benzonatate, enoxaparin, escitalopram, ferrous sulfate, guaifenesin, hydrocodone/acetaminophen, methylprednisolone, methylprednisolone, Montelukast, morphine, ondansetron, pantoprazole.  Patient has been hospitalized since 2/17
MISSED A DOSE; This spontaneous case report was received from a pharmacist (PVX2019-022) on 03-Jan-2019. The report describes a 32-year-old adult male consumer who "missed a dose". The consumer was receiving Vivotif for an unknown indication.  It was reported that the consumer took the first dose of Vivotif on Saturday (29-Dec-2018) and forgot to take the second dose which was due on Monday (31-Dec-2018). The pharmacist stated he advised the consumer to take the next dose on Wednesday, 02-Jan-2019, and continue every other day to finish the course.  The action taken with Vivotif with respect to the event "missed a dose" was not applicable.  The clinical outcome of the event "missed a dose" was unknown.  Company's Comment: The causality of the event "missed a dose" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "missed a dose" was considered as not applicable.
3/29 Facial vesicular lesions with crusting on face & eyelids. 4/4/11 Spoke w/ Mom. Lesions scabbed over.
allergic reaction; This spontaneous case was reported by a consumer and describes the occurrence of HYPERSENSITIVITY (allergic reaction) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HYPERSENSITIVITY (allergic reaction). At the time of the report, HYPERSENSITIVITY (allergic reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported by the reporter.  Treatment medication was not provided by the reporter.   Reporter did not allow further contact
Patient received Pentacel instead of DTap and experienced itchiness, redness and swelling at the site of the injection.  Redness was 14 cm by 9 cm.
Pt. developed approximately 20 pox on trunk, back, face, and legs. 02/15/2002-02/16/2005 approximately 50-100 pox noted. 0 fever-reported  by Monday 02/16/2002
within 3 hours started a fever and chills. By 12 hours later fever even with a dose of tylenol  remained at 103. Next day fever and chills but also included muscles aches. Within 24 hours could not bring fever down below 103+ (even with tylenol and motrin, double dose of each at the same time) and started uncontrollable muscle jerks/spasms. Continued high fever for 4 days along with muscle spasms for 48 hours. Fever broke 4 days later but was left with a sore throat, no taste, no appetite and nausea and diarrhea. 6 days later nausea, diarrhea, and sore throat subsided and left with inability to taste normally. Tastebuds went back to normal around two weeks after vaccine.  The severity of the fever and muscle jerks was the main concern.
First shot left me with a fever of 102 for two days, plus being chilled and migraine. Second shot left me with a fever of 100.5, chilled, and migraine.
Extreme pain in injection site (left shoulder). Had problems lifting arm then and still today (9/6/2011).
Both MMR and Varicella vaccines were administered intramuscularly instead of subcutaneously as recommended. The following symptoms occurred within 12 hours: Inflammation in upper thighs at vaccination site. Low grade fever. Painful to touch and unwillingness to bear weight on legs.
Initial information received from another manufacturer (reference number WAES0710USA01964) on 15 October 2007. The following information is reported verbatim from the other manufacturer's report: "Information has been received on request from the FDA under the Freedom of Information Act regarding a 15 year old female with no known drug or food allergies and a history of symptoms of depression and anxiety with suicidal ideation (SI) on and off who on 05-Sep-2007 was vaccinated intramuscularly into the left arm with a first dose of Gardasil (lot #656371/0181U). Concomitant vaccination on 05-Sep-2007 included an intramuscular injection into the right arm with a first dose of MENACTRA (Lot #U2394BA). On 05-Sep-2007 the patient experienced chest pain, shortness of breath, headache, dizziness, nausea and fever. The patient was given SOLU-MEDROL and BENADRYL intravenously and 2 liters of oxygen nasal cannula with a possible diagnosis of an allergic reaction to MENACTRA, dyspepsia and tachycardia. Diagnostic impression revealed major depressive disorder (MDD), agoraphobia and generalized anxiety. A chest x-ray was within normal limits (WNL). At the time of the report the patient's outcome was unknown. The original reporting source was not provided." "The reporter felt that agoraphobia, chest pain, dizziness, dyspepsia, dyspnoea, generalized anxiety disorder, headache, hypersensitivity, major depression, nausea, pyrexia and tachycardia to be serious events due to hospitalization." "Additional information is not available."
This spontaneous report was received from a nurse regarding multiple unspecified patients of unknown age and gender. The patients' pertinent medical history, drug reactions or allergies and concomitant therapies were not reported. On unknown dates, the patients were vaccinated with an improperly stored doses of PROQUAD (Merck) (dose and route were not reported, lot # L030586, expiry date: 10-FEB-2017). There was no adverse effects reported. Lot number L030586 has been verified to be a valid lot number for PROQUAD (Merck). Albumin status was verified to be rHA. Follow up information was received on 12-FEB-2016 from a healthcare worker regarding a 5 year old female patient. On 18-NOV-2015, the patient was vaccinated with a dose of PROQUAD (Merck). This is one of the several reports from the same source. Additional information has been requested. Patient tab, product tab, event tab and narrative were updated.
Information has been received from a physician concerning a 60 to 65 year old male patient who on 20-OCT-2008 was vaccinated with PNEUMOVAX vaccine (lot # 658673/0990U). On 22-OCT-2008 the patient experienced severe arm pain, swelling and redness that looked like cellulitis. The patient sought unspecified medical attention. This is one of several reports from the same source. Additional information has been requested.